Crossmark

Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours

Crossref DOI link: https://doi.org/10.1186/s13058-018-1089-5

Published Online: 2019-01-07

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Selli, Cigdem

Turnbull, Arran K.

Pearce, Dominic A.

Li, Ang

Fernando, Anu

Wills, Jimi

Renshaw, Lorna

Thomas, Jeremy S.

Dixon, J. Michael

Sims, Andrew H. https://orcid.org/0000-0001-9082-3665
Funding

Funding for this research was provided by:

Breast Cancer Now

H2020 Marie Skłodowska-Curie Actions

Wellcome Trust
License Information

Text and Data Mining valid from 2019-01-07
More Information

Article History

Received: 10 July 2018

Accepted: 19 December 2018

First Online: 7 January 2019

Authors’ information

: Not applicable.

: All patients provided informed consent and sample collection was approved by the local research ethics committee (Lothian Local Research Ethics Committee 03, REC Reference number 07/S1103/26, approval date 13 August 2007).

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.